Literature DB >> 2716734

Interaction of human IgG chimeric antibodies with the human FcRI and FcRII receptors: requirements for antibody-mediated host cell-target cell interaction.

M R Walker1, J M Woof, M Brüggemann, R Jefferis, D R Burton.   

Abstract

Chimeric monoclonal antibodies (McAb), specific for the hapten 5-iodo-4-hydroxy-3-nitrophenacetyl (NIP), expressing human IgG1, IgG2, IgG3 and IgG4 subclass constant domains, have been examined for their ability to interact with the human FcRII receptor. Human red blood cells (RBC) sensitized by each of these McAbs have been assayed for their ability to form rosettes with the human histiocytic lymphoma U937 cell line, human B cell line Daudi and erythroblastoid K562 cell line. IgG1 and IgG3 sensitized RBC formed significant rosettes with the FcR- and FcRII+ Daudi and K562 cell lines, the percentage of cells forming rosettes being directly proportional to the degree of sensitization of the RBC. Bromelin treating Daudi cells did not alter this pattern of reactivity, whereas bromelin treated FcRI+ and FcRII+ U937 cells formed significant resettes with IgG1, IgG3 and IgG4 sensitized RBC, demonstrating a difference in the IgG subclass specificity between human FcRI and FcRII. Murine IgG2b anti-NIP sensitized RBC did not form rosettes with any cell line tested; however, RBC sensitized by some members of a panel of murine IgG1 McAb, specific for the glycophorin A molecule, were able to form rosettes with Daudi, U937 and K562 cells. This interaction was enhanced by bromelin treating the Daudi or U937 cells and can be correlated to the disposition of the epitopes recognized, relative to the target cell membrane, those McAbs recognizing epitopes furthest from the RBC surface being most effective in interacting with FcRII. The data are interpreted in terms of a simple model for antibody-mediated cell--cell interaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2716734     DOI: 10.1016/0161-5890(89)90129-6

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  Epitopes on sialoglycoprotein alpha: evidence for heterogeneity in the molecule.

Authors:  B Gardner; S F Parsons; A H Merry; D J Anstee
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

Review 2.  Can anti-IgE be used to treat allergy?

Authors:  F M Davis; L A Gossett; K L Pinkston; R S Liou; L K Sun; Y W Kim; N T Chang; T W Chang; K Wagner; J Bews
Journal:  Springer Semin Immunopathol       Date:  1993

Review 3.  Selective IgG subclass deficiency: quantification and clinical relevance.

Authors:  R Jefferis; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

4.  Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads.

Authors:  Pratip Nag; Jenney Kim; Vytautas Sapiega; Alan L Landay; James W Bremer; Jiri Mestecky; Patricia Reichelderfer; Andrea Kovacs; Jonathan Cohn; Barbara Weiser; Linda L Baum
Journal:  J Infect Dis       Date:  2004-10-28       Impact factor: 5.226

Review 5.  Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease.

Authors:  Elizabeth A Fitzpatrick; Jin Wang; S E Strome
Journal:  Front Immunol       Date:  2020-03-25       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.